Inhibitory Antibodies

A monoclonal antibody is secreted by a single B lymphocyte clone which can only produce a kind of proprietary antibody against an antigen-determining cluster, and has the characteristics of single biological activity and particular specificity of binding with antigen.

The active sites of monoclonal antibody drugs involve a variety of tumor-related signaling pathways and targets. For example, the most common targets are epidermal growth factor receptor (EGFR), vascular endothelial growth factor (VEGF), and epidermal growth factor receptor -2 (her-2 /neu, or egfr-2). Besides, there is a group of targets that are getting a lot of attention called “immune checkpoints”.

After the activation of immune cells that regulate the anti-tumor immune response, a variety of highly expressed receptors on the surface of immune cells bind to the highly expressed ligands on the surface of tumor cells to reduce the strength of the immune response, thus down-regulating the intensity of tumor-related immune response. These immunoregulatory sites are known as immune checkpoints. Currently, the most widely studied immune checkpoints are PD-1, PD-L1, and CTLA-4.

Targetmol provides xnum monoclonal antibody drugs, including the above immune checkpoint inhibitors and other types of targeted antibody inhibitors, for scientific research only.

Cat. No.	Product name	CAS No.	Purity	Chemical Structure
T76702	Sutimlimab	2049079-64-1	98%	Sutimlimab
T76702	Sutimlimab is a novel monoclonal antibody targeting complement protein C1. Sutimlimab is commonly used as a C1 inhibitor to treat cold agglutina-associated hemol...			Sutimlimab
T76704	Tralokinumab	1044515-88-9	98%	Tralokinumab
T76704	Tralokinumab is a fully human IgG4 monoclonal antibody with a high affinity for IL-13 alone. Tralokinumab's potential anti-inflammatory activity prevents IL-13 r...			Tralokinumab
T76706	Varlilumab	1393344-72-3	98%	Varlilumab
T76706	Varlilumab (CDX-1127) is a novel human IgG1 anti-CD27 monoclonal antibody. Varlilumab has antitumor activity and can be used to study advanced solid tumors.			Varlilumab
T76711	Golimumab	476181-74-5	98%
T76711	Golimumab (CNTO-148) is a potent humanized anti-TNFα IgG1κ monoclonal antibody.Golimumab has anti-inflammatory and anticancer activity, inhibits the production o...
T76713	Inebilizumab	1299440-37-1	98%	Inebilizumab
T76713	Inebilizumab is a humanized anti-CD19 monoclonal antibody with enhanced antibody-dependent cell-mediated cytotoxicity against B cells. Inebilizumab can be used t...			Inebilizumab
T76717	Serplulimab	2231029-82-4	98%
T76717	Serplulimab (HLX 10) is a humanized monoclonal anti-antibody to PD-1. Serplulimab has antitumor activity and can be used in small cell lung cancer and esophageal...
T76718	Brentuximab	2088770-90-3	98%
T76718	Brentuximab is a chimeric antibody targeting CD30 and is a naked antibody to Brentuximab vedotin.Brentuximab has antitumor activity and may be used to study rela...
T76720	Farletuzumab	896723-44-7	98%	Farletuzumab
T76720	Farletuzumab (MORAb-003) is a potent inhibitor of folate receptor-α (FRα). Farletuzumab is a humanized monoclonal antibody with a high affinity for FRα. Farletuz...			Farletuzumab
T76724	Nemolizumab	1476039-58-3	98%	Nemolizumab
T76724	Nemolizumab (CIM331) is a humanized monoclonal antibody against human interleukin-31 receptor A that inhibits the binding and subsequent signal transduction of i...			Nemolizumab
T76726	Zagotenemab	2019133-28-7	98%	Zagotenemab
T76726	Zagotenemab is a humanized antibody against the microtubule-associated protein tau that selectively regulates tau deposits in the brain. Zagotenemab can be used ...			Zagotenemab
T76727	Teprotumumab	1036734-93-6	98%	Teprotumumab
T76727	Teprotumumab is a human monoclonal antibody that blocks the IGF-1 receptor (IGF-1R). Teprotumumab binds to the extracellular α-subunit domain ligand of IGF-1R. T...			Teprotumumab
T76735	Mupadolimab	2451856-97-4	98%	Mupadolimab
T76735	Mupadolimab (CPI-006) is a humanized FC-γR binding deficient IgG1 anti-CD73 antibody with potential anticancer activity and activation of CD73POS B cells.			Mupadolimab
T76739	Bococizumab	1407495-02-6	98%
T76739	Bococizumab(PF-04950615) is a humanized mAb against PCSK9 and an inhibitor of the synthesis of PCSK9 in the liver that reduces the amount of low-density lipoprot...
T76742	Emapalumab	1709815-23-5	98%	Emapalumab
T76742	Emapalumab (NI-0501) is an IgG1 monoclonal antibody that humanizes human monoclonal antibodies against interferon gamma, blocking its binding to cell surface rec...			Emapalumab
T76743	Emibetuzumab	1365287-97-3	98%	Emibetuzumab
T76743	Emibetuzumab is a potent humanized bivalent MET antibody (IgG4 type). Emibetuzumab has antitumor activity, inhibition of HGF-dependent and independent MET pathwa...			Emibetuzumab
T76744	Enokizumab	909875-08-7	98%	Enokizumab
T76744	Enokizumab (MEDI-528) is a monoclonal antibody against interleukin IL-9. Enokizumab can be used to study asthma.			Enokizumab
T76747	Fletikumab	1357158-22-5	98%	Fletikumab
T76747	Fletikumab (NNC0109-0012) is a monoclonal antibody against IL-20 that is often used as an IL-20 inhibitor.Fletikumab is used in the study of rheumatoid arthritis...			Fletikumab
T76749	Zilovertamab	1643432-38-5	98%	Zilovertamab
T76749	Zilovertamab (UC-961) is a humanized anti-ROR1 monoclonal antibody that cuts off the WNT5A-induced ROR1 signaling pathway and shows anti-proliferative activity i...			Zilovertamab
T76750	Cemiplimab	1801342-60-8	98%	Cemiplimab
T76750	Cemiplimab (Anti-Human PD-1) is a human monoclonal antibody against programmed cell death receptor 1 (PD-1) and a checkpoint inhibitor that blocks PD-1/PD-L1 med...			Cemiplimab
T76756	Parsatuzumab	1312797-14-0	98%
T76756	Parsatuzumab (RG 7414) is a humanized monoclonal antibody targeting EGFL7, which is also used as an immunomodulator.Parsatuzumab selectively inhibits the interac...